<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403531</url>
  </required_header>
  <id_info>
    <org_study_id>ICNOIC</org_study_id>
    <nct_id>NCT02403531</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy Followed by Chemoradiotherapy in Esophageal Cancer</brief_title>
  <official_title>A Phase II Randomized Trial of Induction Chemotherapy Versus no Induction Chemotherapy Followed by Definitive Chemoradiotherapy in Patients With Inoperable Thoracic Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mian XI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The contribution of induction chemotherapy before definitive chemoradiotherapy is unknown.
      The purpose of this study was to compare the efficacy and toxicity of induction chemotherapy
      followed by definitive chemoradiotherapy versus no induction chemotherapy in patients with
      inoperable thoracic esophageal squamous cell carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      108 patients were randomized to receive no induction chemotherapy (IC, Arm A) or IC (Arm B)
      before definitive chemoradiotherapy in patients with inoperable thoracic esophageal squamous
      cell carcinoma. Patients assigned to Arm B first received two cycles of 3-weekly schedule of
      IC, consisting of docetaxel 75 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1. The prescribed
      dose of radiotherapy is generally 50-60 Gy/25-28fr. The concomitant chemotherapy is docetaxel
      20 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1, repeated weekly during radiation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>3 months after the treatment (plus or minus 7 days)</time_frame>
    <description>RECIST (Response Evaluation Criteria in Solid Tumors) criteria was used to determine the tumor response. Tumor response was evaluated 3 months after the completion of treatment based on barium esophagography, CT scans, and endoscopy with biopsies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Three years follow-up from the enrollment to the date of death from any cause or date of lost follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>From the date of randomization to the date of disease progression or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>EORTC QLQ-C30 questionnaire was used to assess the quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Concurrent chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to this Arm received concurrent chemoradiotherapy. The prescribed dose of radiotherapy is generally 50-60 Gy/25-28fr. The concomitant chemotherapy is docetaxel 20 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1, repeated weekly during radiation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction chemotherapy plus chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to this Arm first received two cycles of 3-weekly schedule of IC before definitive chemoradiotherapy, consisting of docetaxel 75 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1. The prescribed dose of radiotherapy is generally 50-60 Gy/25-28fr. The concomitant chemotherapy is docetaxel 20 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1, repeated weekly during radiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.</description>
    <arm_group_label>Concurrent chemoradiotherapy</arm_group_label>
    <arm_group_label>Induction chemotherapy plus chemoradiotherapy</arm_group_label>
    <other_name>taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.</description>
    <arm_group_label>Concurrent chemoradiotherapy</arm_group_label>
    <arm_group_label>Induction chemotherapy plus chemoradiotherapy</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>definitive radiotherapy</description>
    <arm_group_label>Concurrent chemoradiotherapy</arm_group_label>
    <arm_group_label>Induction chemotherapy plus chemoradiotherapy</arm_group_label>
    <other_name>radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed squamous cell carcinoma of the esophagus;

          2. Localized, nonmetastatic disease (T1-4, N0-1) confirmed by endoscopic ultrasound (EUS)
             and CT scan (according to UICC TNM version 6);

          3. Absence of distant metastasis of solid organ;

          4. Not suitable for surgery (either for medical reasons or patient's choice);

          5. Age at diagnosis 18 to 70 years;

          6. Eastern Cooperative Oncology Group performance status ≤ 2

          7. No prior cancer therapy;

          8. No history of concomitant or previous malignancy;

          9. Hematologic function: WBC ≥ 4.0×109/L, PLT ≥ 80×109/L, Hb ≥ 10mg/dL;

         10. Renal function: Cr ≤ 1.25×UNL;

         11. Hepatic function: BIL ≤ 1.5×UNL, ALT/AST ≤ 2.5×UNL;

         12. Documented informed consent to participate in the trial.

        Exclusion Criteria:

          1. Younger than 18 or older than 70 years of age;

          2. ECOG performance status of 3 or above;

          3. Other cancer history;

          4. Previous radiotherapy history;

          5. Subjects with distant metastases;

          6. Pregnancy or breast feeding. Women of childbearing age must use effective
             contraception;

          7. Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia,
             unstable angina, myocardial infarction, serious heart valve disease, resistant
             hypertension);

          8. Evidence of bleeding diathesis or serious infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meng-Zhong Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ruhstaller T, Widmer L, Schuller JC, Roth A, Hess V, Mingrone W, von Moos R, Borner M, Pestalozzi BC, Balmermajno S, Köberle D, Terraciano L, Schnider A, Bodis S, Popescu R; Swiss Group for Clinical Cancer Research (SAKK). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol. 2009 Sep;20(9):1522-8. doi: 10.1093/annonc/mdp045. Epub 2009 May 22.</citation>
    <PMID>19465425</PMID>
  </reference>
  <reference>
    <citation>Koo DH, Park SI, Kim YH, Kim JH, Jung HY, Lee GH, Choi KD, Song HJ, Song HY, Shin JH, Cho KJ, Yoon DH, Kim SB. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. Cancer Chemother Pharmacol. 2012 Mar;69(3):655-63. doi: 10.1007/s00280-011-1750-5. Epub 2011 Oct 4.</citation>
    <PMID>21968953</PMID>
  </reference>
  <reference>
    <citation>Ilson DH, Minsky BD, Ku GY, Rusch V, Rizk N, Shah M, Kelsen DP, Capanu M, Tang L, Campbell J, Bains M. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer. 2012 Jun 1;118(11):2820-7. doi: 10.1002/cncr.26591. Epub 2011 Oct 11.</citation>
    <PMID>21990000</PMID>
  </reference>
  <reference>
    <citation>Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov;24(11):2844-9. doi: 10.1093/annonc/mdt339. Epub 2013 Aug 23.</citation>
    <PMID>23975663</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Mian XI</investigator_full_name>
    <investigator_title>Dr. Xi</investigator_title>
  </responsible_party>
  <keyword>Esophageal cancer</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>induction chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

